2 citations
,
October 2000 in “Journal of Investigative Dermatology” AUC and APL are distinct conditions needing careful clinical assessment.
November 2025 in “Journal of Investigative Dermatology” 2 citations
,
July 2025 in “Scientific Reports” Acinetobacter strain A1-4-2 can safely clean water pollutants.
September 2023 in “Journal of the American Academy of Dermatology” 1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
17 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” The excimer laser may help hair regrow in alopecia areata patients.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
July 2024 in “Journal of Investigative Dermatology” 5-ARI therapy may help prevent prostate cancer progression.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
July 2022 in “Skin research and technology” Skin CT can help diagnose rosacea by identifying specific skin features, but should be used with clinical signs to avoid misdiagnosis.
July 2004 in “Hair transplant forum international” The document's conclusion cannot be provided because the document is not available for parsing.
25 citations
,
December 2022 in “Indonesian Journal of Science and Technology” Peanut stem extract has strong antioxidants and moderate cancer-fighting potential.
21 citations
,
March 2022 in “Pharmaceuticals” The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
20 citations
,
January 2010 in “Biological Trace Element Research” 13 citations
,
April 2010 in “Journal of dermatological science” Chemotherapy-induced hair loss is partly due to decreased laminin-511 and increased laminin-332.
4 citations
,
January 2014 in “The Journal of urology/The journal of urology” Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.
2 citations
,
January 2025 in “International Journal of Molecular Sciences” Chitosan-encapsulated Cordyceps militaris reduces lung cell damage from pollution.
1 citations
,
January 2023 in “Biochemical and biophysical research communications” Keratin 79 is linked to liver damage and may help diagnose liver diseases.
May 2025 in “Baghdad Journal of Biochemistry and Applied Biological Sciences” Adiantum capillus-veneris has many health benefits, including fighting bacteria, reducing inflammation, and helping with hair loss and infections.
September 2023 in “Journal of Nutrition and Metabolism” One Ashwagandha extract may help protect cells with its antioxidant properties, while another could promote hair growth.
86 citations
,
December 2002 in “Tissue Antigens” A specific gene change is linked to severe hair loss.
July 2024 in “Journal of Investigative Dermatology” June 2026 in “Frontiers in Medicine” The excimer laser is a promising and safe treatment for frontal fibrosing alopecia.
1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.